AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. The Company’s Human Response Platform (HRP) provides insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. This platform was designed to overcome many of the limitations of traditional approaches to modeling human cancer. The Company’s product candidates include AV-203, Ficlatuzumab, Tivozanib and AV-380. AV-203 inhibits the activity of the ErbB3 receptor and its preclinical studies suggest that neuregulin-1 (NRG1). Ficlatuzumab is a Hepatocyte Growth Factor (HGF), inhibitory antibody. AV-380 is for treatment of cachexia. Tivozanib is a potent, selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).